Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

    NEXT STORY
    Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
    PREV STORY
    Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Pharmaceutical Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Route of Administration ; Application ; End User, and Geography

    author_avatar
    NASDAQ Market News

    Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes

    author_avatar
    NASDAQ Market News

    OPKO Health Reports 2017 Third Quarter Highlights and Financial Results

    RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 20174Kscore utilization increased ...

    author_avatar
    NASDAQ Market News